Pfizer is one of the most prominent names in the health care sector that is working for a disease free, healthier and safer world. The sole business of the company is to produce and sell medicines globally. The company has many successful and popular drugs on their portfolio. The company has been doing a strong business after its deal to AstraZeneca failed in the previous months. It has continued its operations and went on completing the deals with Wyeth and Baxter International Inc.
The company has recently signed two major deals in quick succession which has bolstered its vaccine portfolio. Moreover, after completing a deal with Wyeth Ltd. the company is now among the top ten pharmaceutical companies in India on the basis of market share. After completing the signing of two deals, the company turned its attention to World Anti-Doping Agency (WADA). Hence Pfizer has signed a collaboration deal with World Anti-Doping Agency. The World Anti-Doping Agency (WADA) has added the United States group Pfizer to the list of pharmaceutical companies with which it maintains collaboration agreements.
The deal is considered as a win-win situation for both parties and it will be beneficial for them in the long run. According to the director general of WADA, David Howman said “this deal is a win-win for both parties.”
A reputable journalist David Owen says “The agreement, which covers all new medicines being developed by Pfizer, the company behind Viagra, will allow the US group to share information on pipeline products with a potential for athletic performance misuse, while permitting WADA to pass on intelligence about substances that are being abused by athletes.”
Pfizer is on a roll as the company has global agreements with Roche, Amgen, GlaxoSmithKline (GSK) and Novartis, as well as the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA).
According to the deal between WADA and Pfizer, it is believed that all the medicines that are developed will be assessed by Pfizer’s pharmacists and scientists in order to identify substances with a significant risk of abuse in sport. Such medicines will include stimulatory effects or improved strength and physical endurance.